🇰🇷 South Korea Country × Condition
dyslipidemias Clinical Trials in South Korea
Active clinical trials for dyslipidemias with research sites in South Korea. All data sourced live from ClinicalTrials.gov — updated daily.
Active Trials: 2 // Recruiting: 2 Phases: Phase 4 // Updated: Daily
Total Trials
2
Recruiting Now
2
Country
🇰🇷 South Korea
Active Trials in South Korea (2)
NCT05365438 Phase 4
Recruiting
Atmeg (Atorvastatin and Omega-3 Combination) and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia
Enrollment
105 pts
Country
🇰🇷 South Korea
Seoul National University Bundang H...
View Trial → NCT07523971
Recruiting
Efficacy and Safety of Pitavastatin/Ezetimibe in Dyslipidemia Patients With Metabolic Syndrome: An Observational Study
Enrollment
10,000 pts
Country
🇰🇷 South Korea
JW Pharmaceutical
View Trial → Frequently Asked Questions
How many dyslipidemias clinical trials are active in South Korea?
There are currently 2 active clinical trials for dyslipidemias with sites in South Korea, of which 2 are actively recruiting patients.
How can I join a dyslipidemias clinical trial in South Korea?
To join a dyslipidemias clinical trial in South Korea, select a recruiting trial below and check the eligibility criteria. Contact the trial's principal investigator or the listed site in South Korea directly. All trials listed here are sourced from ClinicalTrials.gov, the official U.S. registry of clinical studies.
What phases are dyslipidemias trials in South Korea?
Active dyslipidemias trials in South Korea span Phase 4. Phase I trials test safety, Phase II test efficacy, and Phase III compare against standard treatments in larger patient populations.
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology